BGI Genomics

The main business of the company is to provide research services and comprehensive precision medicine testing solutions for scientific research institutions, enterprises and public institutions, medical institutions, and social health organizations through multi-omics big data technologies such as genetic testing, mass spectrometry testing, and bioinformatics analysis.Adhering to the vision of "Genomic Science for the Benefit of Humanity," BGI Genomics is committed to advancing life science research, applying life big data, and improving global healthcare standards. Based on genomic research achievements and the application of precision testing technologies in public health, the company strives to accelerate technological innovation, reduce birth defects, strengthen tumor prevention and control, mitigate the harm of major diseases to humanity, achieve precise treatment of infections, and comprehensively support precision medicine.The company relies on a world-leading bioinformatics R&D, transformation, and application platform, with hundreds of high-throughput sequencers, mass spectrometers, and high-performance computers, providing strong support for data generation, storage, and analysis.Headquartered in Shenzhen, China, the company has branches and medical testing laboratories in major cities such as Beijing, Tianjin, Wuhan, Shanghai, Guangzhou, and Hong Kong, as well as overseas centers and core laboratories in Europe, the Americas, and the Asia-Pacific region, forming a network layout that "covers all of China and radiates globally."The company mainly serves domestic and international universities and research institutions, independent medical testing laboratories, pharmaceutical companies, as well as hospitals and healthcare institutions at all levels, corporate clients, and individual customers both domestically and internationally. Currently, the company's business covers more than 100 countries and regions worldwide, including over 2,000 research institutions and 2,300 medical institutions in China, of which more than 300 are tertiary hospitals; and over 3,000 overseas medical and research institutions in collaboration across Europe, the Americas, and the Asia-Pacific region.